Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib, Eribulin, and Trastuzumab in Pretreated HER2+ Breast Cancer
NCT05458674Phase 2Active, not recruiting
- Sponsor
- Criterium
- Start
- Jan 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in breast cancer, sponsored by Criterium. Started Jan 2024; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05458674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458674.